BIO Protocol is a launch platform and liquidity protocol for decentralized science (DeSci), aiming to promote global biotechnology innovation through decentralized means. It connects patients, scientists, and investors to jointly fund and own tokenized biotechnology projects and intellectual property (IP).

Vision of BIO Protocol:

• Accelerate Scientific Breakthroughs: Support individuals, rather than institutions, in leading biotechnology funding and commercialization.

• Liquidity and Community: Build efficient markets and on-chain communities to collaborate around the most promising early-stage scientific projects.

• Tokenization of Intellectual Property: Provide incentives and structure for distributed research and development outside the traditional pharmaceutical industry, creating more valuable scientific IP.

How BIO Protocol Addresses Pain Points in the Biotechnology Sector:

• Decentralized Funding: Open investment channels for anyone to support promising projects.

• Resource Integration: Aggregate data, funding, and talent to reduce the cost of innovation.

• Risk Diversification: Reduce the risk of biotechnology investments through portfolio management.

• Global Collaboration: Attract global scientists and capital to drive groundbreaking research.

• Shared Ownership: Achieve joint ownership of intellectual property through tokenization.

• Early Liquidity: Provide liquidity support for biotechnology assets.

• Open Governance: Eliminate intermediate barriers in the traditional funding process.

Core Products of BIO Protocol:

1. BioDAO Launchboard

   • The first batch of 8 DAOs has completed the acceleration program with a total market value exceeding $300 million.

   • The latest BioDAO raised an initial $6.8 million, which was 13 times oversubscribed.

2. Acceleration Tools

   • Provide legal frameworks, branding, and Web3 tool support to help communities establish BioDAOs.

   • Cumulatively raised 7.37millionforresearchareas,withatokenizedIPportfoliovaluedatover43 million.

3. Liquidity Protocol

   • Guide liquidity through BIO Genesis, with a total value locked (TVL) exceeding $50 million.

   • Approximately 29,800 network token holders.

Empowerment of $BIO:

• Governance Rights: Holders can participate in the governance of the protocol and BioDAOs.

• Whitelist Access: Priority access to BioDAO funding rounds and IP tokens.

• Curatorial Management: Support high-quality BioDAO launches and provide funding and liquidity.

• Ecosystem Connectivity: BIO holds a basket of DeSci tokens, enabling network synergies through supporting BioDAOs.

• Liquidity Earnings: Earn transaction fees from tokenized assets in the protocol treasury.

Private and Public Funding of BIO Protocol:

Private Funding:

• Before the seed round, the project raised 0.9millionwithavaluationofapproximately35 million.

• In the seed round, the project raised 1.4millionwithavaluationofapproximately69 million.

Public Funding:

• The public funding process is through open BIO Genesis auctions, consisting of three rounds:

  1. In Genesis Round 1, the project raised 6.2millionwithavaluationofapproximately85 million.

  2. In Genesis Round 2, the project raised 18.2millionwithavaluationofapproximately142 million.

  3. In Genesis Round 2.5, the project raised 3.5millionwithavaluationofapproximately219 million.

Token Economics:

• Initial Circulating Supply: 1,296,529,168 BIO (39.05% of the maximum supply)

• Total Token Supply: 3,320,000,000 BIO

• Binance Launchpool Allocation: 99,600,000 BIO (3% of the total supply)

Future Potential of $BIO:

From the DeSci perspective, BIO combines scientific research with blockchain technology, potentially reshaping traditional research paradigms. It is an emerging and yet fully untapped field that combines the narratives of scientific research and blockchain, with the potential to attract traditional research funding and high-end talent. If BIO can attract a large influx of cutting-edge talent, research projects, and funding, its future market capitalization ceiling could be very impressive. However, investment always requires rational thinking, especially for projects in emerging fields like $BIO, where potential and risk coexist

BIO Protocol is a launch platform and liquidity protocol for decentralized science (DeSci), aiming to promote global biotechnology innovation through decentralized means. It connects patients, scientists, and investors to jointly fund and own tokenized biotechnology projects and intellectual property (IP).

Vision of BIO Protocol:

• Accelerate Scientific Breakthroughs: Support individuals, rather than institutions, in leading biotechnology funding and commercialization.

• Liquidity and Community: Build efficient markets and on-chain communities to collaborate around the most promising early-stage scientific projects.

• Tokenization of Intellectual Property: Provide incentives and structure for distributed research and development outside the traditional pharmaceutical industry, creating more valuable scientific IP.

How BIO Protocol Addresses Pain Points in the Biotechnology Sector:

• Decentralized Funding: Open investment channels for anyone to support promising projects.

• Resource Integration: Aggregate data, funding, and talent to reduce the cost of innovation.

• Risk Diversification: Reduce the risk of biotechnology investments through portfolio management.

• Global Collaboration: Attract global scientists and capital to drive groundbreaking research.

• Shared Ownership: Achieve joint ownership of intellectual property through tokenization.

• Early Liquidity: Provide liquidity support for biotechnology assets.

• Open Governance: Eliminate intermediate barriers in the traditional funding process.

Core Products of BIO Protocol:

1. BioDAO Launchboard

   • The first batch of 8 DAOs has completed the acceleration program with a total market value exceeding $300 million.

   • The latest BioDAO raised an initial $6.8 million, which was 13 times oversubscribed.

2. Acceleration Tools

   • Provide legal frameworks, branding, and Web3 tool support to help communities establish BioDAOs.

   • Cumulatively raised 7.37millionforresearchareas,withatokenizedIPportfoliovaluedatover43 million.

3. Liquidity Protocol

   • Guide liquidity through BIO Genesis, with a total value locked (TVL) exceeding $50 million.

   • Approximately 29,800 network token holders.

Empowerment of $BIO:

• Governance Rights: Holders can participate in the governance of the protocol and BioDAOs.

• Whitelist Access: Priority access to BioDAO funding rounds and IP tokens.

• Curatorial Management: Support high-quality BioDAO launches and provide funding and liquidity.

• Ecosystem Connectivity: BIO holds a basket of DeSci tokens, enabling network synergies through supporting BioDAOs.

• Liquidity Earnings: Earn transaction fees from tokenized assets in the protocol treasury.

Private and Public Funding of BIO Protocol:

Private Funding:

• Before the seed round, the project raised 0.9millionwithavaluationofapproximately35 million.

• In the seed round, the project raised 1.4millionwithavaluationofapproximately69 million.

Public Funding:

• The public funding process is through open BIO Genesis auctions, consisting of three rounds:

  1. In Genesis Round 1, the project raised 6.2millionwithavaluationofapproximately85 million.

  2. In Genesis Round 2, the project raised 18.2millionwithavaluationofapproximately142 million.

  3. In Genesis Round 2.5, the project raised 3.5millionwithavaluationofapproximately219 million.

Token Economics:

• Initial Circulating Supply: 1,296,529,168 BIO (39.05% of the maximum supply)

• Total Token Supply: 3,320,000,000 BIO

• Binance Launchpool Allocation: 99,600,000 BIO (3% of the total supply)

Future Potential of $BIO:

From the DeSci perspective, BIO combines scientific research with blockchain technology, potentially reshaping traditional research paradigms. It is an emerging and yet fully untapped field that combines the narratives of scientific research and blockchain, with the potential to attract traditional research funding and high-end talent. If BIO can attract a large influx of cutting-edge talent, research projects, and funding, its future market capitalization ceiling could be very impressive. However, investment always requires rational thinking, especially for projects in emerging fields like $BIO, where potential and risk coexist